Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
